For research and educational purposes only. Not medical advice.

VK2735 Reference

Educational, not medical advice reference for VK2735: GLP-1, Fat Loss, Metabolic; regulatory status, evidence posture, source review, and schedu…

Reference summary

The VENTURE Phase 2 13-week subcutaneous weekly obesity trial (Viking sponsor disclosure, 2024) reported substantial placebo-adjusted weight loss across the dose-ascending arms. Detailed methods and final analyses are pending peer-reviewed publication. The oral VK2735 program is at earlier stages (Phase 1 / 2 single-ascending- and multiple-ascending-dose work disclosed via sponsor channels). Phase 3 trial registration is the next regulatory milestone.

Regulatory and posture

Categories
GLP-1, Fat Loss, Metabolic
Aliases
Viking Therapeutics VK2735, Dual GLP-1 / GIP receptor agonist, Weekly subcutaneous and oral formulations
Evidence posture
human - Investigational. Trial readouts to date are sponsor-disclosed; the peer-reviewed publication trail is still developing. Phase 3 has not started. Do not present as available, approved, or compoundable.
Regulatory status
Investigational. VK2735 is Viking Therapeutics' dual GLP-1 / GIP receptor agonist. There is no FDA-approved drug label. Phase 2 results were reported through Viking's sponsor disclosure in 2024 from the subcutaneous weekly VENTURE Phase 2 obesity trial; an oral VK2735 formulation is also in early-stage development. VK2735 is not on FDA's approved bulk-substances list for traditional 503A compounding; any gray-market preparation sold under the VK2735 name does not inherit the sponsor's trial data.
Content review status
investigational verified

Selected public sources

Related tools